Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade

Key Points

• Truist upgraded DNTH to a "buy" and raised its price target from $63 to $110, prompting a pre-market gap where shares opened at $78.90 and last traded around $80.67 on heavy volume.
• Dianthus announced an early "GO" decision in the Phase 3 CAPTIVATE trial for claseprubart, keeping the 300mg S.C. Q2W dose and planning to ask regulators to remove the 600mg option, a notable clinical/regulatory de‑risking move.
• Even with several analysts bullish (average rating "Moderate Buy" and target ≈ $73.50), Dianthus missed Q4 EPS estimates (reported -$1.43 vs. -$0.97 est) and showed extremely negative margins, highlighting near‑term profitability and valuation concerns.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price gapped up before the market opened on Monday after Truist Financial raised their price target on the stock from $63.00 to $110.00. The stock had previously closed at $65.20, but opened at $78.90. Truist Financial currently has a buy rating on the stock. Dianthus Therapeutics shares last traded at $80.67, with a volume of 1,905,070 shares.

Other equities analysts have also recently issued reports about the stock. HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a "buy" rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Wedbush lifted their target price on Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Finally, Jefferies Financial Group increased their price target on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a "buy" rating in a report on Monday, February 2nd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $73.50.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early GO decision in Phase 3 CAPTIVATE — Dianthus announced an early "GO" decision following an interim responder analysis: the trial hit the GO criteria of 20 confirmed responders with fewer than 40 planned Part A completers. The company will keep the Part A dose at 300mg/2mL S.C. Q2W and plans to engage regulators about removing the 600mg/4mL option — a substantive clinical/regulatory de‑risking step for claseprubart. Article Title
• Positive Sentiment: Analyst upgrade / price-target lift — Truist raised its price target from $63 to $110 and maintained a "buy" rating, signalling increased upside expectations and likely supporting buying interest. Article Title
• Neutral Sentiment: Investor access / upcoming commentary — Dianthus hosted (and scheduled) a conference call and webcast to discuss the interim responder analysis results, which should provide additional color and could drive intraday volatility depending on management tone and Q&A. Article Title
• Neutral Sentiment: Market commentary / valuation focus — Recent write-ups evaluate DNTH after a strong run-up in the share price; these pieces can amplify debate on whether current valuation already prices the program successes. Article Title
• Negative Sentiment: Q4 earnings miss and widening loss — Dianthus reported Q4 EPS of ($1.43) vs. consensus (~$0.97 loss), missing estimates by ~$0.46; revenue was $0.57M (above an estimate of $0.40M) but the company posted extremely negative margins and ROE. The larger-than-expected loss raises near-term profitability concerns and could limit upside despite the clinical news. Article Title

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics in the fourth quarter valued at $43,000. Seven Fleet Capital Management LP bought a new stake in Dianthus Therapeutics during the 4th quarter worth about $604,000. Invesco Ltd. boosted its stake in shares of Dianthus Therapeutics by 125.9% during the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company's stock worth $4,182,000 after buying an additional 56,560 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $550,000. Finally, Voloridge Investment Management LLC grew its holdings in shares of Dianthus Therapeutics by 80.5% in the 4th quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company's stock valued at $1,627,000 after acquiring an additional 17,612 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Stock Performance

The company has a fifty day moving average price of $48.42 and a two-hundred day moving average price of $40.78. The company has a market cap of $3.46 billion, a P/E ratio of -22.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, March 10th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.